Associate Professor
Adam CollisonProfile page
Associate Professor
School of Medicine and Public Health
- Associate ProfessorSchool of Medicine and Public Health
- 0240420219 (Work)
- 40420219 (Mobile)
- John Hunter Hospital Site, Lookout Road, Lambton Hts, NSW, Australia
BIOGRAPHY
To be a healthy adult, you need to grow up well in early life. Most chronic diseases that influence adult quality of life and life expectancy begin in childhood, thus, prevention and early intervention are key to reducing their impact.
Allergy is the fastest growing chronic disease in Australia affecting around 4.1 million people. While asthma has been recognised as a national health priority since 1999, there is increasing interest in food allergy, with as many as one in ten Australian infants testing positive to a food allergy. Alarmingly, the rate of hospital admissions for anaphylaxis has increased fourfold over the past 25 years. Food allergy associated diseases such as Eosinophilic Oesophagitis (a chronic condition of an inflamed food pipe) have also been increasing over the past two decades.
My vision is to undertake cutting-edge research in close collaboration with other world-leading scientists and medical doctors, to develop better diagnostics and treatments for these common and debilitating diseases. We need to address the urgent need to better understand the development of asthma and allergy in early life, so as to deliver lifelong better health outcomes to the growing number of Australians impacted by these chronic diseases.
My research has focused upon identification of novel therapeutic targets and molecular biomarkers to assist in better identification and treatment of asthma and food allergy in order to address currently unmet clinical needs. I have identified a novel proinflammatory signalling pathway downstream of tumour necrosis factor apoptosis inducing ligand (TRAIL) that is dysregulated in human asthmatics and eosinophilc oesophagitis patients. I have effectively targeted this pathway to therapeutic benefit in mouse models of rhinovirus induced allergic airways exacerbation – the current cause of over 80% of childhood asthma attacks presenting to hospital. This patent was licensed to Israeli based drug development company Proteologics in 2013.
I have a particular interest in the epigenetic regulation of asthma, and have modulated miRNA to therapeutic benefit in vivo using mouse models of allergic airways disease.
I have identified and patented a novel biomarker that in early studies enables stratification of peanut allergy severity, and allows accurate prediction of anaphylaxis risk upon subsequent food challenge. This is the first test in the world to measure food allergy severity and has the potential to radically modify the management of peanut allergy.
Research Expertise: Eosinophilic Oesophagitis; Microbiology; Immunology; Food Allergy; Allergy; Asthma; Paediatrics
UNIVERSITY OF NEWCASTLE APPOINTMENTS
- Associate ProfessorUniversity of Newcastle, School of Medicine and Public Health, Australia12 Sep 2011 - present
DEGREES
- Bachelor of Biomedical SciencesUniversity of Newcastle12 Dec 2005
- PhD (Biomedical Sciences)University of Newcastle3 Feb 2012
- Bachelor of Biomedical Sciences (Hons)University of Newcastle11 Dec 2006
PROFILE TYPE
- Academic Staff
SUSTAINABLE DEVELOPMENT GOALS
- 10 Reduced Inequalities
- 4 Quality Education
- 3 Good Health and Well Being
SUPERVISION AVAILABILITY
- Available - Senior Supervisor
DISCIPLINE
- Focus Area not applicable